Development of Streptococcus pneumoniae Vaccines Using Live Vectors
AbstractStreptococcus pneumoniae still causes severe morbidity and mortality worldwide, especially in young children and the elderly. Much effort has been dedicated to developing protein-based universal vaccines to conquer the current shortcomings of capsular vaccines and capsular conjugate vaccines, such as serotype replacement, limited coverage and high costs. A recombinant live vector vaccine delivering protective antigens is a promising way to achieve this goal. In this review, we discuss the researches using live recombinant vaccines, mainly live attenuated Salmonella and lactic acid bacteria, to deliver pneumococcal antigens. We also discuss both the limitations and the future of these vaccines. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Wang, S.; Curtiss III, R. Development of Streptococcus pneumoniae Vaccines Using Live Vectors. Vaccines 2014, 2, 49-88.
Wang S, Curtiss III R. Development of Streptococcus pneumoniae Vaccines Using Live Vectors. Vaccines. 2014; 2(1):49-88.Chicago/Turabian Style
Wang, Shifeng; Curtiss III, Roy. 2014. "Development of Streptococcus pneumoniae Vaccines Using Live Vectors." Vaccines 2, no. 1: 49-88.